{ "items": [ "\n\n
\n \n 19 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build immunity.
\n \n\n\n \n 12 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford has secured a critical professorship in vaccinology for the future following a gift of \u00a33.33 million from the Sa\u00efd family. The gift will enable Professor Sarah Gilbert, the inaugural post holder, to continue her ground-breaking research in the field, while also helping to ensure that Oxford remains at the forefront of vaccine development for generations to come.
\n \n\n\n \n 23 October 2020\n \n
\n\n \n \n \n\n \n \n \nBvlgari and the University of Oxford\u2019s Jenner Institute announce the next stage of their pledge to build a pandemic-free future by awarding the inaugural Bvlgari Scholarships.
\n \n\n\n \n 22 September 2020\n \n
\n\n \n \n \n\n \n \n \nOn Friday 18 September, Prime Minister Boris Johnson visited the Old Road Campus Research Building to meet senior researchers from the Medical Sciences Division. The Prime Minister heard about the developments, success and challenges at Oxford in relation to the University\u2019s ongoing COVID-19 research.
\n \n\n\n \n 2 September 2020\n \n
\n\n \n \n \n\n \n \n \nA new arm of the ongoing global clinical trials of the ChAdOx1 nCoV-19 vaccine led by AstraZeneca has launched in the US to assess safety, efficacy and immunogenicity of the vaccine for the prevention of COVID-19.
\n \n\n\n \n 20 July 2020\n \n
\n\n \n \n \n\n \n \n \nThe results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
\n \n\n\n \n 20 July 2020\n \n
\n\n \n \n \n\n \n \n \nThe Phase 1 data shows that the vaccine raised no safety concerns, did not lead to any unexpected symptoms in those who received it, and was very similar to other vaccines of this type.
\n \n\n\n \n 10 July 2020\n \n
\n\n \n \n \n\n \n \n \nA generous gift of \u00a33.5 million from Lakshmi Mittal and his family has secured the future of a critical professorship in vaccinology at the University. The post, which is currently held by Professor Adrian Hill, will be known as the Lakshmi Mittal and Family Professorship of Vaccinology in recognition of this support.
\n \n\n\n \n 27 June 2020\n \n
\n\n \n \n \n\n \n \n \nVolunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin America\u2019s first phase 3 COVID-19 clinical trial. The trial officially began on Saturday 20th June and will enrol 5,000 volunteers across the country. Vaccinations will take place in Sao Paulo, Rio de Janeiro and a site in the Northeast of Brazil. The Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials on 2nd June, which are being conducted in partnership with AstraZeneca.
\n \n\n\n \n 25 June 2020\n \n
\n\n \n \n \n\n \n \n \nThe Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group\u2019s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.
\n \n\n\n \n 17 June 2020\n \n
\n\n \n \n \n\n \n \n \nProf Sarah Gilbert from the Jenner Institute is speaking at a video linked Global Covid-19 vaccine congress on Monday 21st June 2020 organised by the International Society for Vaccines. The\u00a0congress\u00a0is\u00a0free\u00a0to scientists with\u00a0an\u00a0interest\u00a0in\u00a0COVID\u201019\u00a0vaccines (pre\u2010registration\u00a0required).
\n \n\n\n \n 5 June 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford\u2019s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
\n \n\n\n \n 4 June 2020\n \n
\n\n \n \n \n\n \n \n \nOn 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
\n \n\n\n \n 3 June 2020\n \n
\n\n \n \n \n\n \n \n \nOn April 30, the University of Oxford and AstraZeneca announced an agreement for the global development and distribution of the University\u2019s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. A Phase I/II clinical trial of the Oxford vaccine began in April in the UK to assess safety and immune response in over 1,000 healthy volunteers aged 18 to 55 years across several trial centres in southern England. As the vaccine trials move to Phase III, a larger population is being enrolled consisting of 10,000 participants in the UK with AstraZeneca enrolling 30,000 particpants in the US. On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.
\n \n\n\n \n 2 June 2020\n \n
\n\n \n \n \n\n \n \n \nOn 13 May Professor Sarah Gilbert gave a short talk and participated in an informal discussion with ambassadors of the United Nations member states, hosted by the UK mission. Here is a summary of her talk.
\n \n\n\n \n 22 May 2020\n \n
\n\n \n \n \n\n \n \n \nUniversity of Oxford researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers. The phase I trial in healthy adult volunteers began in April. More than 1,000 immunisations have been completed and follow-up is currently ongoing. \r\nThe next study will enrol up to 10,260 adults and children and will involve a number of partner institutions across the country.
\n \n\n\n \n 22 May 2020\n \n
\n\n \n \n \n\n \n \n \nThe purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers. This study aims to assess how well people across a broad range of ages could be protected from COVID-19 with this new vaccine called ChAdOx1 nCoV-19. It will also provide valuable information on safety aspects of the vaccine and its ability to generate good immune responses against the virus. Follow the title link to learn more.
\n \n\n\n \n 21 May 2020\n \n
\n\n \n \n \n\n \n \n \nAstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford\u2019s vaccine widely accessible around the world in an equitable manner. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall. The development programme includes a Phase III clinical trial with 30,000 participants and a paediatric trial.
\n \n\n\n \n 19 May 2020\n \n
\n\n \n \n \n\n \n \n \nWe are writing in response to the article published on Forbes online on 16th May by William Haseltine relating to the BioRxiv preprint publication \u2018ChAdOx1 nCoV-19 vaccination prevents SARSCoV-2 pneumonia in rhesus macaques' by van Doremalen et al (2020).
\n \n\n\n \n 18 May 2020\n \n
\n\n \n \n \n\n \n \n \nThe Government has announced \u00a365.5 million of new funding for the vaccine being developed at the University of Oxford as coronavirus vaccine trials accelerate.
\n \n\n